BMS-354825: a novel drug with potential for the treatment of imatinib-resistant chronic myeloid leukaemia

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.14, Iss.1, 2005-01, pp. : 89-91

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Imatinib mesylate-resistant cells were present in a man with chronic myeloid leukaemia (CML) before treatment with the drug

Inpharma, Vol. 1, Iss. 1390, 2003-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Dasatinib Treatment for Imatinib Resistant or Intolerant Patients with Chronic Myeloid Leukaemia

By Li J Xu G Yu S He L Guo L

The Journal of International Medical Research, Vol. 39, Iss. 2, 2011-03 ,pp. : 337-347

Field House Publishing

Access to resources Recommend Favorite

Imatinib mesylate in the treatment of chronic myeloid leukaemia

By Druker Brian J

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 6, 2003-06 ,pp. : 963-971

Informa Healthcare

Access to resources Recommend Favorite

Is AMN-107 a step forward from imatinib in the treatment of chronic myeloid leukaemia?

By Doggrell Sheila A

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 8, 2005-08 ,pp. : 1063-1066

Informa Healthcare

Access to resources Recommend Favorite

Imatinib: A Review of its Use in Chronic Myeloid Leukaemia

By Moen Marit D. McKeage Kate Plosker Greg L. Siddiqui M. Asif A.

Drugs, Vol. 67, Iss. 2, 2007-01 ,pp. : 299-320

Adis International

Access to resources Recommend Favorite